CellPryme
CAR‑T enhancement platform
PreclinicalActive
Key Facts
About Prescient Therapeutics
Australian early‑stage oncology biotech leveraging a GGT‑1 inhibitor and novel CAR‑T platforms to address unmet‑need cancers.
View full company profileCAR‑T enhancement platform
Australian early‑stage oncology biotech leveraging a GGT‑1 inhibitor and novel CAR‑T platforms to address unmet‑need cancers.
View full company profile